openPR Logo
Press release

Androgenic Alopecia Therapeutics - Pipeline Analysis GSK, Almirall, Allergan, RepliCel Life Sciences Inc.

12-03-2018 06:09 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: P&S Intelligence

Androgenic Alopecia Therapeutics - Pipeline Analysis GSK,

The study analyzed that the androgenic alopecia therapeutics pipeline comprises approximately 24 active drug candidates in different stages of development.

Download free report sample at: https://www.psmarketresearch.com/market-analysis/androgenic-alopecia-therapeutics-pipeline-analysis/report-sample

Androgenic alopecia is a genetic disorder that affects both men and women and is characterized by hair loss in both the sexes. Androgenic alopecia is also known as male-pattern baldness in men and female-pattern baldness in women. The predisposing factors for androgenic alopecia include allergies, burns, irritants, injuries, infections, and toxins.

*Various Collaborations for Androgenic Alopecia Therapeutics Drug Development

In August 2017, Aclaris Therapeutics, Inc. acquired Confluence Life Sciences, Inc., a privately held biotechnology company for a consideration of $10 million in cash and issued approximately 350,000 shares of its common stock, with a value of approximately $10 million on the closing date to expand the dermatological pipeline of Aclaris Therapeutics, Inc.

Browse report at: https://www.psmarketresearch.com/market-analysis/androgenic-alopecia-therapeutics-pipeline-analysis

Some of the key players developing drugs for the treatment of androgenic alopecia therapeutics include GlaxoSmithKline plc, Almirall S.A., Allergan plc, RepliCel Life Sciences Inc. and others.

*Positive Clinical Results of Androgenic Alopecia Therapeutics Candidates

The positive clinical results of androgenic alopecia drug candidates have been driving the pipeline growth. Many drug candidates have shown positive clinical results and are proceeding further towards development. In February 2016, Cassiopea S.p.A. reported the top-line results from the proof of concept, Phase II clinical trial of Breezula (CB-03-01), in androgenic alopecia and it was found that Breezula, met both its two pre-defined co-primary efficacy endpoints, increase in total area hair count within 1 cm2 (TAHC) and subject hair growth assessment (HGA) at six months. Breezula also demonstrated favorable safety profile.

Pre-Purchase Inquiry at: https://www.psmarketresearch.com/send-enquiry?enquiry-url=androgenic-alopecia-therapeutics-pipeline-analysis

About P&S Intelligence

P&S Intelligence, a brand of P&S Market Research, is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.

Contact:
P&S Intelligence
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Androgenic Alopecia Therapeutics - Pipeline Analysis GSK, Almirall, Allergan, RepliCel Life Sciences Inc. here

News-ID: 1414153 • Views:

More Releases from P&S Intelligence

Global E-Signature Market Thrives with Rising Security Concerns and Cloud Adoption
Global E-Signature Market Thrives with Rising Security Concerns and Cloud Adopti …
According to the latest market research study published by P&S Intelligence, the e-signature market generated revenue of USD 2,580.3 million in 2023 and is anticipated to achieve a compound annual growth rate (CAGR) of 26.7% from 2024 to 2030, reaching USD 13,407.3 million by 2030. This market expansion can be attributed to increased safety concerns among enterprises, growing government support, and the rising adoption of innovative technologies in emerging countries
Neurology Had the Major Share in the AI-Based Medical imaging Market
Neurology Had the Major Share in the AI-Based Medical imaging Market
The AI-based medical imaging market will generate USD 11,921.4 million 2030, powering at a robust rate of 30.4% by the end of this decade. The key factors powering the industry include the increasing occurrence of chronic ailments, growing requirement for medical services for the elderly populace, and increasing research and development expenditure in the healthcare industry. Furthermore, the incessant progression in imaging tech and the increase in the
Remote Access Provided by Cloud Category Fuels Call Center AI Market
Remote Access Provided by Cloud Category Fuels Call Center AI Market
In 2021, the call center AI market generated sales worth $1,982.9 million, and it is expected to contribute $12,910.6 million in 2030, progressing at a rate of 23.1% from 2021 to 2030, ascribed to the growing up requirements for improved data analytics to manage customer inquiries with the real-time response to improve customer engagement through social media. In order to pace up the 4th industrial revolution, businesses across various industries
Growing Demand for CSM System Will Drive the Customer Engagement Solutions Market
Growing Demand for CSM System Will Drive the Customer Engagement Solutions Marke …
The total value of the customer engagement solutions market was $18,186.8 million in 2021, and it will rise at a growth rate of above 10% in the near future, to reach $43,398.9 million by 2030. The major reasons behind the growth of this industry are growing usage of such solutions in serval industries like healthcare, telecommunications, BFSI and FMCG. North America will grow the fastest with a rate of 10.5% in

All 5 Releases


More Releases for Androgenic

Insights on the Androgenic Alopecia Drug Market to 2027 | Industry Statistics, E …
The global androgenic alopecia drug market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The growing prevalence of hair loss, technological advancements in alopecia treatment, and the rise in prevalence of chronic diseases that are associated with hair loss are some of the major factors driving the market. According to data published by the American Hair Loss Association, it was stated that over 95.0% of
(2020-2026) Androgenic Alopecia Therapeutics MARKET GROWTH, EMERGING TRENDS, TOP …
QY Research offers its latest report on the Global Androgenic Alopecia Therapeutics Market Size, Status and Forecast 2020-2026 that includes comprehensive analysis on a range of subjects such as competition, segmentation, regional expansion, and market dynamics. Some of the Major key players operating in this Report are: Johnson & Johnson, Merck, GlaxoSmithKline, Astellas Pharma, Cipla, Almirall, Sun Pharma, Reddy's Laboratories, Concert Pharmaceuticals, RiverTown Therapeutics, Brickell Biotech, BiologicsMD, Aclaris Therapeutics The report has
Androgenic Alopecia Therapeutics Pipeline Analysis Report -Clinical Trials & Res …
The study analyzed that the androgenic alopecia therapeutics pipeline comprises approximately 24 active drug candidates in different stages of development. Androgenic alopecia is a genetic disorder that affects both men and women and is characterized by hair loss in both the sexes. Androgenic alopecia is also known as male-pattern baldness in men and female-pattern baldness in women. The predisposing factors for androgenic alopecia include allergies, burns, irritants, injuries, infections, and
Global Androgenic Alopecia Drug Market Trends, Sales, Industry Analysis and Dema …
A fresh report has been added to the wide database of Market Research Hub (MRH) titled “Global Androgenic Alopecia Drug Market Research Report (2018-2025)” which provides an outlook of current market value as well as the expected forecast of Rate on Investment (ROI) with growing CAGR of XX% by the end of 2025. The report also studies the Androgenic Alopecia Drug market worldwide, especially in North America, China, Europe, Southeast
Androgenic Alopecia Therapeutics Pipeline Analysis - Clinical Trials & Results, …
Androgenic Alopecia is a genetic disorder characterized by the hair loss in both men and women. The disease occurs when terminal hair is gradually converted into indeterminate, and finally into vellus, hair. The predisposing factors for androgenic alopecia include allergies, burns, irritants, injuries, infections and toxins. Access Detailed Report Summary at: https://www.psmarketresearch.com/market-analysis/androgenic-alopecia-therapeutics-pipeline-analysis Androgenetic alopecia in men has been associated with several other medical conditions including enlargement of the prostate
Global Androgenic Alopecia Clinical Trials Industry Review :H1-2017 | Diseases M …
Market Research Hub's clinical trial report, Global Androgenic Alopecia Clinical Trials Review, H1, 2017, provides an overview of Androgenic Alopecia clinical trials scenario. This report provides top line data relating to the clinical trials on Androgenic Alopecia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Request Free Sample Report@ http://www.marketresearchhub.com/enquiry.php?type=S&repid=1068385 The report offers coverage of disease clinical trials by region, country (G7